達飛控股(01826.HK)發行最多800萬美元可換股債 淨籌6170萬港元
格隆匯1月9日丨達飛控股(01826.HK)公佈,於2020年1月8日,認購人與公司訂立認購協議,據此,公司向認購人發行而認購人按初始換股價每股換股股份1.22港元(較收市價每股股份1.08港元溢價約12.96%)認購本金總額最多800萬美元票息率6%可換股債券,期限為364日,可根據公司選擇延長六個月。
於可換股債券按初始換股價悉數轉換後,將會發行最多5114.75萬股換股股份,相當於公告日期公司已發行股本約3.84%。
據悉,所得款項淨額估計為6170萬港元。其中,約5600萬港元未來潛在收購事項與業務發展;及(ii)約570萬港元作為集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.